Exosome Diagnostics is a leading developer of fluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are packaged and shed into all biofluids, including blood, urine and cerebrospinal fluid, providing a stable source for intact, disease-specific genetic material. The company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/11/14 | $27,000,000 | Series B |
Arcus Ventures CD Ventures Forbion Capital Partners Monashee Capital NGN Capital QIAGEN Tiger Partners | undisclosed |
| 01/07/16 | $60,000,000 | Series B |
Arcus Ventures Blue Ridge Capital CD Ventures Forbion Capital Partners NGN Capital QIAGEN Tiger Management | undisclosed |
